Panmure Gordon Reaffirms “Buy” Rating for Cambridge Cognition (LON:COG)

Cambridge Cognition (LON:COG)‘s stock had its “buy” rating reissued by equities research analysts at Panmure Gordon in a research report issued on Monday, MarketBeat reports. They currently have a GBX 56 target price on the stock. Panmure Gordon’s price objective indicates a potential upside of 100.00% from the stock’s current price.

Cambridge Cognition Stock Down 1.8%

COG stock opened at GBX 28 on Monday. The firm has a market cap of £13.04 million, a PE ratio of -7.37 and a beta of 0.72. Cambridge Cognition has a 1 year low of GBX 23.90 and a 1 year high of GBX 47. The company has a fifty day simple moving average of GBX 29.84 and a 200 day simple moving average of GBX 31.56. The company has a current ratio of 0.65, a quick ratio of 0.96 and a debt-to-equity ratio of 92.53.

Cambridge Cognition Company Profile

Cambridge Cognition Holdings Plc, a neuroscience technology company, develops and markets near-patient cognitive testing techniques in the United States, United Kingdom, the European Union, and internationally. The company offers CANTAB digital cognitive assessment platform for drug development by enabling pharmaceutical companies to take new therapeutics from preclinical consultancy to pivotal studies and approval, as well as supports sponsors to enhance recruitment, develop safe and effective treatments, and enhance research and development efficiency.